Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs KLA Corp. (KLAC) Price & Performance

Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs KLA Corp. — how do they compare? Gilead Sciences, Inc. trades at $135.34 (market cap $168.35B), while KLA Corp. trades at $204.94 (market cap $261.92B). The key difference: KLA Corp. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.

GILDKLAC
Market Cap
$168.35B$261.92B
Sector
HealthTechnology
52-Week High
$155.80$301.71
52-Week Low
$110.56$84.39
Enterprise Value
$191.42B$263.17B
Dividend Yield
2.42%0.46%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About KLA Corp.

KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.

Read more on KLAC